The Food and Drug Administration recently approved the first drug to treat Alexander disease, a rare, progressive and often fatal neurological disorder that can affect motor, cognitive and autonomic functions like heart rate and breathing. The drug, Zanvastro, is the first and only disease-modifying treatment for Alexander disease. Until now, treatment of the disease has been limited to symptom management.